MedTrace Logo

The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line

NCT03205735 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-07-02

No results posted yet for this study

Summary

An observational study of a prospective, analytical, monocentric cohort which does not modify the patient care because the phenotyping of the dihydropyrimidine déshydrogénase DPD (lymphocyte activity) is already carried out in routine hospital. The analysis will be based on clinical, radiological and biological criteria.

Conditions

  • Metastatic or Locally-advanced Digestive Cancer

Interventions

DIAGNOSTIC_TEST

lymphocyte DPD dosage

lymphocyte DPD dosage in peripheral blood

Sponsors & Collaborators

  • Centre Antoine Lacassagne

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-29
Primary Completion
2021-09-29
Completion
2021-12-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03205735 on ClinicalTrials.gov